Industry Pushes CMS For Details On Centralized Coverage Review Of IDE Trials
This article was originally published in The Gray Sheet
Executive Summary
Whether they support centralized review or not, device manufacturers want CMS to provide more detail on how the process would work – including timelines, the extent of manufacturer interactions with agency staff, and how appeals would be handled.
You may also be interested in...
CMS Will Switch To Centralized Coverage Review Of IDE Trials, But Not Until 2015
The Medicare agency is delaying, by one year, its plan to replace local coverage review of investigational device exemption studies with a centralized process. New scientific and ethical criteria for covered IDE studies will also go into effect in 2015 – minus controversial provisions that would have favored pivotal studies with a statistical superiority design.
New AdvaMed Exec Donald May Weighs In On Reimbursement Priorities
In an interview with “The Gray Sheet,” Donald May, the new executive vice president of payment and health care delivery policy at AdvaMed, discusses priorities in his new role with the association.
Final Coverage-With-Evidence-Development Guidance Delayed By CMS Staff Cuts
The CMS coverage and analysis group has had to divert its attention from finishing a CED guidance to finalizing proposed changes to the process for awarding Medicare coverage for IDE trials, primarily due to staff cuts, says Louis Jacques, who heads the group.